Amarin Corporation plc announced that the Company's Board of Directors has appointed Patrick Holt as Chief Executive Officer, effective immediately. Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role. Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience.

He most recently served as president of Cordis, Cardinal Healths global interventional cardiovascular business where he led a turnaround of the business, followed by a transaction process which led to its successful sale. Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck. Patrick Holt most recently served as president of Cordis, Cardinal Healths global interventional cardiovascular business and as member of Cardinal Health Incs global operating committee.

In this role, Mr. Holt led a successful turnaround that included a return to revenue growth, a refocused R&D strategy, as well as sustained enhancements in operational effectiveness delivering margin expansion. Subsequently, he led the transaction process which culminated in the sale of Cordis to Hellman &Friedman in 2021 for an enterprise value in excess of $1 billion. He also previously served as president of Cardinal Health in Asia-Pacific.

Prior to his time at Cardinal Health, he served in a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck. Mr. Holt is an independent non-executive director and audit committee member of Hugel Inc. He earned a bachelors degree in biochemistry and chemistry from Monash University, Australia and is a graduate of Harvard Business School.